Pharmaceutical Technology3h
City Therapeutics launches with $135m Series A funding
City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...
ENDPOINTS NEWS3h
Base­camp rais­es $60M to trav­el the globe and fill AI da­ta gaps, signs deal with David Liu
London-based startup Basecamp Research has closed a $60 million Series B round that will help expand its genomic database and ...
PipelineReview.com6h
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines ...
STAT7h
Scholar Rock sees SMA data boosting obesity effort
Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
ENDPOINTS NEWS21h
John Maraganore's RNAi biotech City Ther­a­peu­tics de­buts with $135M Se­ries A
City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...
Biotech veteran John Maraganore raises $135 million for his ‘next-generation RNAi’ startup
City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...
FierceBiotech22h
City Therapeutics breaks ground with $135M and blueprints from RNAi expert John Maraganore
A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...